Biocon is currently trading at Rs. 328.40, up by 11.85 points or 3.74% from its previous closing of Rs. 316.55 on the BSE.
The scrip opened at Rs. 321.00 and has touched a high and low of Rs. 329.50 and Rs. 319.55 respectively. So far 153726 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 404.60 on 21-Jan-2025 and a 52 week low of Rs. 260.00 on 19-Apr-2024.
Last one week high and low of the scrip stood at Rs. 329.50 and Rs. 295.30 respectively. The current market cap of the company is Rs. 39409.70 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 21.02% and 18.34% respectively.
Biocon’s subsidiary -- Biocon Biologics has inked a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA (aflibercept).
Biocon Biologics and Regeneron have executed the settlement agreement to dismiss the pending appeal at the United States Court of Appeals for the Federal Circuit (USCAFC) of patent US11084865 (‘865 patent) and the pending litigation at the U.S. District Court for the Northern District of West Virginia, Clarksburg Division. This agreement enables the company to launch ‘YESAFILI’ in the United States in the second half of calendar year 2026 or earlier in certain circumstances. The terms of the settlement are confidential.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.85 |
Dr. Reddys Lab | 1173.55 |
Cipla | 1525.50 |
Lupin | 2018.35 |
Zydus Lifesciences | 859.10 |
View more.. |